Landos Biopharma, Inc.

NasdaqCM:LABP Stock Report

Market Cap: US$71.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Landos Biopharma Future Growth

Future criteria checks 0/6

Landos Biopharma's earnings are forecast to decline at 37.1% per annum. EPS is expected to grow by 37.6% per annum.

Key information

-37.1%

Earnings growth rate

37.6%

EPS growth rate

Pharmaceuticals earnings growth17.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated24 May 2024

Recent future growth updates

Recent updates

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Mar 22
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer

Sep 06

Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Aug 19
Companies Like Landos Biopharma (NASDAQ:LABP) Could Be Quite Risky

Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

May 05
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?

Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Nov 17
Landos Biopharma (NASDAQ:LABP) Is In A Strong Position To Grow Its Business

Landos Biopharma posts positive outcome from omilancor End-of-Phase 2 FDA meeting

Jun 14

Landos Biopharma (LABP) Investor Presentation - Slideshow

Jun 08

We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

May 04
We Think Landos Biopharma (NASDAQ:LABP) Needs To Drive Business Growth Carefully

Earnings and Revenue Growth Forecasts

NasdaqCM:LABP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-45N/AN/A1
12/31/2024N/A-26N/AN/A1
3/31/2024N/A-25-21-21N/A
12/31/2023N/A-22-20-20N/A
9/30/2023N/A-21-19-19N/A
6/30/2023N/A-23-25-25N/A
3/31/2023N/A-30-37-37N/A
12/31/2022N/A-39-46-46N/A
9/30/2022N/A-54-54-54N/A
6/30/2022N/A-59-59-58N/A
3/31/202218-43-31-31N/A
12/31/202118-38-28-27N/A
9/30/202118-30-24-23N/A
6/30/202118-25-17-17N/A
3/31/2021N/A-34-32-32N/A
12/31/2020N/A-30-23-23N/A
9/30/2020N/A-22-17-17N/A
6/30/2020N/A-17-16-16N/A
3/31/2020N/A-16-12-12N/A
12/31/2019N/A-13-10-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LABP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LABP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LABP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if LABP's revenue is forecast to grow faster than the US market.

High Growth Revenue: LABP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if LABP's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/26 06:34
End of Day Share Price 2024/05/24 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Landos Biopharma, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin Garner KalleyCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.
Christopher HowertonJefferies LLC